Ocular Therapeutix Taps EYLEA Launch Architect as Global Chief Commercial Officer

Event summary

  • Ocular Therapeutix appoints David W. Robinson as Global Chief Commercial Officer effective January 21, 2026.
  • Robinson previously led the launch of EYLEA® at Regeneron and served as Chief Marketing Officer at Merck.
  • Robinson will oversee global commercial strategy for AXPAXLI™, Ocular’s investigational retinal disease treatment.
  • Current Chief Commercial Officer Steve Meyers will continue leading DEXTENZA® marketing efforts.
  • AXPAXLI is in Phase 3 trials for wet AMD and non-proliferative diabetic retinopathy.

The big picture

Ocular Therapeutix is positioning itself for a major commercial push with the appointment of David W. Robinson, a veteran of blockbuster retina drug launches. This move comes as the company advances its Phase 3 trials for AXPAXLI, aiming to capture market share in wet AMD and diabetic retinopathy. Robinson’s experience in both U.S. and international markets could be pivotal as Ocular seeks to compete with established players like Regeneron.

What we're watching

Launch Execution
Whether Robinson can replicate his EYLEA success with AXPAXLI, given the competitive retinal disease market.
Regulatory Timeline
The pace at which Ocular can advance its NDA timeline and secure approval for AXPAXLI.
Global Expansion
How effectively Ocular can scale its commercial operations internationally.